Korean Idiopathic Pulmonary Fibrosis Registry

Idiopathic Pulmonary Fibrosis Clinical Trial

Official title:

Korean Idiopathic Pulmonary Fibrosis Registry

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04160715
• Other study ID #: 1.1
• Status: Recruiting
• Start date: January 2016
• Est. completion date: December 2026

Study information

• Verified date: November 2019
• Source: Seoul National University Hospital
• Contact: Jong Sun Park, MD
• Email: jspark.im[@]gmail.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

This is a multicenter prospective registry of IPF patients in South Korea. The Seoul National University Bundang Hospital is the coordination center for the Korean IPF Registry built by a collaboration of the Korean Interstitial Lung Diseases (ILD) Study Group.

Description:

Korean ILD Study Group includes investigators of 30 hospitals. Demographic, pulmonary function, laboratory data, chest CT findings and hospital course of IPF patients are collected.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3000
• Est. completion date: December 2026
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 100 Years

Eligibility

Inclusion Criteria:

• IPF patients diagnosed by multidisciplinary discussion

Exclusion Criteria:

• Other interstitial lung diseases except for IPF

• connective tissue disease-related ILD

• exposure-related ILD

Related Conditions & MeSH terms

• Fibrosis
• Idiopathic Interstitial Pneumonias
• Idiopathic Pulmonary Fibrosis
• Pulmonary Fibrosis

Locations

Country	Name	City	State
Korea, Republic of	Seoul National University Bundang Hospital	Seongnam-si

Sponsors (1)

Lead Sponsor	Collaborator
Seoul National University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	survival of IPF	lung function change (FVC, DLCO)	through study completion, an average of 1 year
Secondary	survival	death rate	through study completion, an average of 1 year
Secondary	acute exacerbation	rate of acute exacerbation	through study completion, an average of 1 year
Secondary	incidence of comorbidity	incidence of lung cancer	through study completion, an average of 1 year